MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

Search

Inmode Ltd

Uždarymo kaina

SektoriusSveikatos priežiūra

13.71 -0.44

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

13.69

Max

13.84

Pagrindiniai rodikliai

By Trading Economics

Pajamos

5.2M

27M

Pardavimai

11M

104M

P/E

Sektoriaus vid.

9.378

56.063

Pelno marža

26.022

Darbuotojai

660

EBITDA

5.7M

31M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+28.14% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-27

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-177M

850M

Ankstesnė atidarymo kaina

14.15

Ankstesnė uždarymo kaina

13.71

Naujienos nuotaikos

By Acuity

50%

50%

141 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Inmode Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-06 23:17; UTC

Uždarbis

Samsung Forecasts Record First-Quarter Operating Profit

2026-04-06 23:00; UTC

Karštos akcijos

Stocks to Watch: Health Insurers, Mawson, Owlet

2026-04-06 22:13; UTC

Pagrindinės rinkos jėgos

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

2026-04-06 21:46; UTC

Įsigijimai, susijungimai, perėmimai

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

2026-04-06 17:09; UTC

Pagrindinės rinkos jėgos

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

2026-04-06 16:56; UTC

Svarbiausios naujienos

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

2026-04-06 14:47; UTC

Pagrindinės rinkos jėgos

Stereotaxis Shares Rise on FDA Clearance for Synchrony

2026-04-07 00:00; UTC

Svarbiausios naujienos

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

2026-04-06 23:58; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

2026-04-06 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

2026-04-06 23:36; UTC

Rinkos pokalbiai

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

2026-04-06 23:15; UTC

Rinkos pokalbiai

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

2026-04-06 22:52; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-06 22:52; UTC

Rinkos pokalbiai

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

2026-04-06 22:14; UTC

Rinkos pokalbiai

Correction to Live Cattle Futures Article

2026-04-06 20:56; UTC

Rinkos pokalbiai

Mexican Private Consumption Fell in January -- Market Talk

2026-04-06 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-04-06 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-06 19:58; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-06 19:58; UTC

Rinkos pokalbiai

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

2026-04-06 19:11; UTC

Rinkos pokalbiai

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

2026-04-06 19:06; UTC

Rinkos pokalbiai

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

2026-04-06 19:03; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-04-06 19:03; UTC

Rinkos pokalbiai

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

2026-04-06 18:36; UTC

Įsigijimai, susijungimai, perėmimai

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

2026-04-06 17:59; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

2026-04-06 17:13; UTC

Įsigijimai, susijungimai, perėmimai

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

2026-04-06 16:33; UTC

Rinkos pokalbiai

Oil Futures Steady as Market Awaits Trump -- Market Talk

2026-04-06 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-06 14:59; UTC

Uždarbis

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Akcijų palyginimas

Kainos pokytis

Inmode Ltd Prognozė

Kainos tikslas

By TipRanks

28.14% į viršų

12 mėnesių prognozė

Vidutinis 17.67 USD  28.14%

Aukščiausias 21 USD

Žemiausias 15 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Inmode Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

5 ratings

1

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

14.1 / 14.44Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

141 / 349 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Inmode Ltd

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.
help-icon Live chat